[{"id":"1144aa34-c3c9-4b7d-b690-4787d1aa6238","acronym":"GALLANT-1","url":"https://clinicaltrials.gov/study/NCT05240131","created_at":"2022-02-15T16:53:16.051Z","updated_at":"2024-07-02T16:35:09.872Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).","source_id_and_acronym":"NCT05240131 - GALLANT-1","lead_sponsor":"Galecto Biotech AB","biomarkers":" PD-L1 • LGALS3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • LGALS3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • selvigaltin (GB1211)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-04-12"},{"id":"5cbbdbd0-828a-4f3e-b2da-6d260cfea60d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913388","created_at":"2023-06-22T19:11:35.572Z","updated_at":"2024-07-02T16:35:10.707Z","phase":"Phase 2","brief_title":"GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT05913388","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" LGALS3","pipe":"","alterations":" ","tags":["LGALS3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • selvigaltin (GB1211)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2024-04-09"},{"id":"36ca1f5c-c2f6-4841-9b20-252eb2f23150","acronym":"","url":"https://clinicaltrials.gov/study/NCT04987996","created_at":"2021-08-03T18:52:59.526Z","updated_at":"2024-07-02T16:35:46.330Z","phase":"Phase 2","brief_title":"GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients","source_id_and_acronym":"NCT04987996","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" CD8 • IL2RA • CCR7 • CD27 • LGALS3 • FAS • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["CD8 • IL2RA • CCR7 • CD27 • LGALS3 • FAS • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • belapectin (GR-MD-02)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2023-06-06"},{"id":"f639df2f-b80b-4b0e-9bef-2bba3806e588","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496260","created_at":"2021-01-18T12:02:16.669Z","updated_at":"2024-07-02T16:36:16.063Z","phase":"","brief_title":"Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy","source_id_and_acronym":"NCT02496260","lead_sponsor":"Henry Ford Health System","biomarkers":" GDF15 • LGALS3 • CRP • MPO • NPPB","pipe":"","alterations":" ","tags":["GDF15 • LGALS3 • CRP • MPO • NPPB"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2022-03-03"}]